Kennedy-Wilson Holdings Files Definitive Proxy for $10.90/Share Take-Private Merger Vote

summarizeSummary

Kennedy-Wilson Holdings filed a definitive proxy statement for a special shareholder meeting on June 10, 2026, to vote on its take-private merger at $10.90 per share, a 45.9% premium over the unaffected price, with a supermajority vote excluding insider shares.

check_boxKey Events

• Definitive Proxy Filed for Take-Private Merger

  The company filed a definitive proxy statement (DEFM14A) for a special meeting on June 10, 2026, to vote on the proposed take-private merger. This follows a preliminary proxy statement filed on April 27, 2026, and an amended SC 13E3 filing on the same date, providing comprehensive details for the transaction.

• Merger Consideration and Premium

  Shareholders will receive $10.90 in cash per share, representing a 45.9% premium over the unaffected closing price of $7.47 on November 4, 2025, the last trading day prior to the public disclosure of the initial proposal.

• Shareholder Vote with Supermajority Condition

  The merger requires approval by a majority of all outstanding voting power and, critically, an affirmative vote of at least two-thirds of the outstanding voting power, excluding shares owned by the Consortium Parties and their affiliates. This 'Supermajority Voting Condition' was added via an amendment to the merger agreement on March 15, 2026, in response to litigation, enhancing protection for unaffiliated shareholders.

• Insider Rollover and Voting Agreements

  Key executives (William J. McMorrow, Matthew Windisch, In Ku Lee) and Fairfax affiliates, forming the Consortium, will roll over 22,341,393 shares of common stock and certain equity awards into the private company, and have entered into voting and support agreements to vote in favor of the merger.

auto_awesomeAnalysis

Kennedy-Wilson Holdings has filed a definitive proxy statement (DEFM14A) for a special meeting on June 10, 2026, to vote on its take-private merger. This filing finalizes the terms for shareholders to receive $10.90 per share in cash, representing a significant 45.9% premium over the unaffected closing price of $7.47 on November 4, 2025. The transaction, valued at approximately $1.65 billion in equity funding from Fairfax, includes a crucial procedural safeguard: approval requires a two-thirds affirmative vote of outstanding voting stock, explicitly excluding shares owned by the Consortium Parties and their affiliates. This supermajority voting condition, added in response to litigation, provides substantial protection for unaffiliated shareholders. The Special Committee, with independent advisors, negotiated the terms, which also allow for two ordinary course quarterly dividends of $0.12 per share prior to the vote. Upon completion, the company will become privately held and its common stock will be delisted.